Home Cart Sign in  
Chemical Structure| 438190-29-5 Chemical Structure| 438190-29-5

Structure of SMI-4a
CAS No.: 438190-29-5

Chemical Structure| 438190-29-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SMI-4a is a potent inhibitor of Pim1 with IC50 of 17 nM, modestly potent to Pim-2, does not significantly inhibit any other serine/threonine- or tyrosine-kinases.

Synonyms: TCS-PIM-1-4a

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SMI-4a

CAS No. :438190-29-5
Formula : C11H6F3NO2S
M.W : 273.23
SMILES Code : O=C(NC/1=O)SC1=C/C2=CC=CC(C(F)(F)F)=C2
Synonyms :
TCS-PIM-1-4a
MDL No. :MFCD01152003
InChI Key :NGJLOFCOEOHFKQ-YVMONPNESA-N
Pubchem ID :1361334

Safety of SMI-4a

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H317-H319
Precautionary Statements:P280-P305+P351+P338

Related Pathways of SMI-4a

epigenetics
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • Pim1

    Pim1, IC50:17 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MCF-7/TaxR cells 5 nM 2 days To investigate the effect of SMI-4a on paclitaxel-resistant cells, the results showed that the combination of paclitaxel and SMI-4a synergistically inhibited the growth of MCF-7/TaxR cells. PMC6224402
Mouse bone marrow-derived macrophages (BMDMs) 3.3 μM, 10 μM, 30 μM 2 h SMI-4a inhibited NLRP3 inflammasome activation, dose-dependently suppressing the cleavage of pro-IL-1β and pro-caspase-1. PMC10329339
Human THP-1 cells 30 μM 45 min SMI-4a inhibited NLRP3 inflammasome activation, reducing IL-1β secretion. PMC10329339
CD4+ T cells 20 μM 72 h Inhibition of PIM1 reduced the proportion of Th1 and Th17 cells and increased the proportion of Treg cells, attenuating the pathogenicity of CD4+ T cells. PMC9532430
HEK293T cells 0.1 μM 30 min To evaluate the inhibitory effect of SMI-4a on PIM1 kinase and its impact on GSK-3 kinase activity. The results showed that SMI-4a effectively inhibited PIM1 kinase activity, thereby preventing GSK-3 phosphorylation at the S10 site. PMC3475679
Raji cells 40 μM In all cell lines, SMI4a caused a marked reduction in cell number and viability. PMC4672512
Ramos cells 40 μM In all cell lines, SMI4a caused a marked reduction in cell number and viability. PMC4672512
OCI-Ly10 cells 40 μM In all cell lines, SMI4a caused a marked reduction in cell number and viability. PMC4672512
OCI-Ly3 cells 40 μM In all cell lines, SMI4a caused a marked reduction in cell number and viability. PMC4672512

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
nude mice MCF-7/TaxR xenograft model intraperitoneal injection 60 mg/kg three times per week for two weeks To investigate the effect of SMI-4a on paclitaxel-resistant tumors, the results showed that the combination of paclitaxel and SMI-4a significantly inhibited the growth of MCF-7/TaxR tumors. PMC6224402
Mice Experimental Autoimmune Uveitis (EAU) model Oral 60 mg/kg Once daily for 14 consecutive days Inhibition of PIM1 significantly alleviated EAU symptoms, reduced the proportion of Th1 and Th17 cells, and increased the proportion of Treg cells. PMC9532430

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.66mL

0.73mL

0.37mL

18.30mL

3.66mL

1.83mL

36.60mL

7.32mL

3.66mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories